Revolution Medicines’ Rasonque received FDA approval last month for metastatic pancreatic cancer treatment, marking a significant development in a disease category that had seen no major breakthroughs in more than four decades. Clinical data demonstrated the drug nearly doubled median overall survival for patients. However, the approval triggered immediate closure of the manufacturer’s expanded access program, creating accessibility challenges for patients and families who were in the process of obtaining the medication through that pathway.
The central issue involves timing misalignment between regulatory approvals and insurance coverage implementation. When early access programs close following FDA approval, commercial insurance coverage often remains unavailable for weeks or months while payers complete administrative and technical procedures necessary to begin covering new medications. This gap poses particular challenges for pancreatic cancer patients, given the disease’s aggressive nature and limited survival timeframes.
Kelsey Solano’s experience illustrates these complications. Her husband Juan was diagnosed with stage 3 pancreatic cancer in January 2025 and initially underwent successful surgery followed by chemotherapy. The cancer recurred within months, advancing to stage 4. As Juan completed a clinical trial at Fred Hutchinson Cancer Center, the family was finalizing paperwork for Revolution’s expanded access program when FDA approval was announced. The approval forced them to pursue commercial insurance coverage instead, leading Solano to make 61 phone calls within 48 hours attempting to navigate the system.
Revolution Medicines operates a support program called (ON)PATH designed to assist patients during the transition to commercial access and to provide free medication to uninsured or underinsured individuals. However, when Solano contacted the program, she was told it could only help patients with pending prior authorization requests from insurers. Aetna indicated it could not submit such requests because the drug had not yet been added to its system, leaving Solano and her medical team unable to proceed despite their efforts to help.
Other patients experienced similar obstacles. A Medicare patient treated by hematologist-oncologist Arturo Loaiza-Bonilla received a denial letter citing that Rasonque was not properly listed with the FDA as a Part D eligible drug. After Loaiza-Bonilla publicly shared the denial on social media, the pharmacy benefit manager OptumRx reversed course and approved the patient’s coverage. However, other patients at the same institution remained waiting for responses from their insurance providers.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI